European Notebook: Data Transparency And Adaptive Licensing Move Forward
More clinical trials move to Denmark, Sanofi’s Viehbacher moves to Boston, and analysts suggest thwarted Pfizer’s next strategic move may be to use contingent value rights in a future attempt for AstraZeneca, plus more in this month’s notebook.
You may also be interested in...
A move toward centralized institutional review board approval of study protocols could reduce clinical trial delays; House Energy and Commerce Committee also is looking at optimizing use of real-world data in the post-market setting.
In finalizing its policy on publishing clinical study reports, EMA stresses redactions of commercially confidential information will be rare, but critics still say it is favoring the pharma industry.
Sanofi CEO says firms and other healthcare stakeholders all need to work together, but “no good deed goes unpunished.”